SCIB1 Plus Nivolumab/Ipilimumab Generates ORR of 85% in Advanced Unresectable Melanoma
Source: OncLive, April 2024
SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.
First-line treatment with the DNA vaccine SCIB1 in combination with nivolumab (Opdivo) and ipilimumab (Yervoy) elicited an overall response rate (ORR) of 85% in patients with advanced, unresectable melanoma (n = 13), according to data from stage 1 of the phase 2 SCOPE trial (NCT04079166) presented at the 2024 AACR Annual Meeting.
Findings showed that among the 11 responders, 1 patient experienced a confirmed complete response, and 10 patients achieved confirmed partial responses at 19 weeks and beyond. One patient had stable disease, and another patient had progressive disease. Twenty-four patients have now received SCIB1 as part of the study.